Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase

Journal of Infectious Diseases

Volumn 201, Issue 7, 2010, Pages 1054-1062

  Von Wyl, Viktor ^a   Ehteshami, Maryam ^f   Symons, Jori ^g   Bürgisser, Philippe ^c   Nijhuis, Monique ^g   Demeter, Lisa M ^h   Yerly, Sabine ^d   Böni, Jürg ^b   Klimkait, Thomas ^e   Schuurman, Rob ^c   Ledergerber, Bruno ^a   Götte, Matthias ^f   Günthard, Huldrych F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g UNIVERSITY OF ROCHESTER   (United States)

^h UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

CELL LINE; DNA, VIRAL; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LAMIVUDINE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS; SELECTION, GENETIC; STATISTICS, NONPARAMETRIC; ZIDOVUDINE;

EID: 77749316883     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/651168     Document Type: Article

References (29)

1. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008;16:138-145
2. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. MoI Cell 1999;4:35-43.
3. Kemp SD, Shi C, Bloor S, Harrigan PR, Mellors JW, Larder BA. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L2′,3′-dideoxy-3′-thiacytidine. J Virol 1998;72:5093-5098
4. 4. Nikolenko GN, Palmer S, Maldarelli F, Mellors JW, Coffin JM, Pathak VK. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sei USA 2005; 102:2093-2098 (Pubitemid 40262017)
5. 5. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, et al. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′azido-3′-deoxythymidine resistance. Proc Natl Acad Sci USA 2007; 104: 317-322 (Pubitemid 46068029)
6. 6. Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3′-azido-3′-deoxythymidine resistance. J Virol 2007;81:6837-6845 (Pubitemid 46986620)
7. 7. Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, Mellors JW. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3′-azido-3′-dideoxythymidine. J Virol 2007;81:7852-7859 (Pubitemid 47101471)
8. Ehteshami M, Götte M. Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility. AIDS Rev 2008; 10:224-235
9. Yap SH, Sheen CW, Fahey J, et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007;4:e335.
10. Ehteshami M, Beilhartz GL, Scarth BJ, et al. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3′-azido-3′-deoxythymidine through both RNase H-dependent and -independent mechanisms. J Biol Chem 2008; 283:22,222-232
11. Hachiya A, Kodama EN, Sarafianos SG, et al. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 2008; 82:3261-3270
12. 12. Cane PA, Green H, Fearnhill E, Dunn D. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS 2007;21:447-455 (Pubitemid 46263255)
13. Brehm JH, Mellors JW, Sluis-Cremer N. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry 2008; 47:14,020-27
14. Delviks-Frankenberry KA, Nikolenko GN, Boyer PL, et al. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc Natl Acad Sci U S A 2008; 105:10,943-948
15. von WyI V, Bürgisser P, Yerly S, et al. Evolution of reverse transcriptase connection domain mutations in patients on antiretroviral therapy. Antivir Ther 2008; 13(Suppl 3):A47.
16. 16. Gotte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 2000; 74: 3579-3585 (Pubitemid 30180301)
17. 17. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J Virol 2002;76:3248-3256 (Pubitemid 34224526)
18. Naeger LK, Margot NA, Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir Ther 2001;6:115-126
19. 19. Diallo K, Oliveira M, Moisi D, Brenner B, Wainberg MA, Götte M. Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2002;46:2254-2256 (Pubitemid 34665925)
20. Demeter LM, Hughes MD, Coombs RW, et al. Predictors of virologic and clinical outcomes in HIV-1 -infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann Intern Med 2001;135:954-964
21. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-733
22. Stanford University HIV Drug Resistance Database. http://hivdb.stanford. edu/pages/clinicalStudyData/ACTG320.html. Accessed 25 January 2010.
23. 23. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-868 (Pubitemid 29126872)
24. 24. von Wyl V, Yerly S, Boni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007; 167:1782-1790 (Pubitemid 47403067)
25. 25. Nijhuis M, Schuurman R, de Jong D, et al. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis 1997; 176:398-405. (Pubitemid 27328761)
26. Boucher CA, Keulen W, van Bommel T, et al. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother 1996;40:2404-2409
27. Le Grice SF, Grüninger-Leitch F. Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur J Biochem 1990; 187:307-314
28. Zelina S, Sheen CW, Radzio J, Mellors JW, Sluis-Cremer N. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrob Agents Chemother 2008;52:157-163
29. Back NK, Nijhuis M, Keulen W, et al. Reduced replication of 3TCresistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15:4040-4049